NCT03231969View on ClinicalTrials.gov

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

October 11, 2017

Study Completion Date

October 11, 2017

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Bilastine 0.2%

1 drop in each eye at 3 separate times during a 25 day period.

DRUG

Bilastine 0.4%

1 drop in each eye at 3 separate times during a 25 day period.

DRUG

Bilastine 0.6%

1 drop in each eye at 3 separate times during a 25 day period.

DRUG

Bilastine 0%

1 drop in each eye at 3 separate times during a 25 day period.

Trial Locations (1)

01810

Ora Clinical Research Center, Andover

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Faes Farma, S.A.

INDUSTRY

NCT03231969 - A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model | Biotech Hunter | Biotech Hunter